scholarly journals Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials

2020 ◽  
Vol 9 (11) ◽  
pp. 3656-3667
Author(s):  
Makoto Endo ◽  
Shunji Takahashi ◽  
Nobuhito Araki ◽  
Hideshi Sugiura ◽  
Takafumi Ueda ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase Ii ◽  
Tumor Response ◽  
Time Lapse ◽  
Pooled Analysis ◽  
Two Phase ◽  
Phase Ii Clinical Trials

scholarly journals Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials

2021 ◽  
Vol 11 ◽  
Author(s):  
Bi-Cheng Wang ◽  
Bo-Hua Kuang ◽  
Bo-Ya Xiao ◽  
Guo-He Lin
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Randomized Clinical Trials ◽  
Objective Response ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
First Line ◽  
Open Label ◽  
Advanced Soft Tissue Sarcoma

BackgroundDoxorubicin/Adriamycin (ADM) alone or combined with ifosfamide (IFO) (AI) is available for previously untreated advanced soft tissue sarcoma (ASTS). However, the clinical choice between them remains controversial. In this pooled analysis, we comprehensively compared the efficacy and tolerability of AI versus ADM in patients with ASTS.MethodsPubMed, Web of Science, EMBASE, and Cochrane Library were systematically searched from inception to April 14, 2021. Eligible studies were randomized clinical trials comparing AI to ADM. The primary outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Discontinuation rate (DR) and toxic death (TD) were explored as secondary outcomes.ResultsOverall, three open-label randomized phase 2/3 clinical trials with a total of 1108 newly diagnosed ASTS patients were enrolled. Between AI and ADM, pooled hazard ratios were 0.93 (95% confidence interval 0.58-1.50, p = 0.78) for OS and 0.85 (0.57-1.25, p = 0.41) for PFS. While pooled risk ratios for ORR, DR, and TD were 1.37 (0.94-1.99, p = 0.10), 1.04 (0.74-1.46, p = 0.82), and 0.68 (0.19-2.36, p = 0.54) respectively. No publication bias was observed across the studies.ConclusionIn the first-line setting, adding IFO to ADM failed to benefit ASTS patients against ADM alone, even with comparable tolerability.

scholarly journals Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

2014 ◽  
Vol 25 (12) ◽  
pp. 2425-2432 ◽  
Author(s):  
A. Le Cesne ◽  
M. Ouali ◽  
M.G. Leahy ◽  
A. Santoro ◽  
H.J. Hoekstra ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Phase Iii Clinical Trials

scholarly journals SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Matthias Kroiss ◽  
Maria-Elisabeth Goebeler ◽  
Camilo Jimenez ◽  
Uwe Malzahn ◽  
Martin Fassnacht ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Adrenocortical Carcinoma ◽  
Two Phase ◽  
Phase Ii Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document